BCX 1470 is primarily used in research settings as a selective inhibitor of factor D, a key enzyme in the alternative complement pathway. Its application is significant in studying inflammatory and autoimmune diseases, where the alternative complement pathway plays a critical role. Researchers utilize BCX 1470 to investigate the mechanisms of diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and other complement-mediated disorders. By inhibiting factor D, BCX 1470 helps in understanding the role of the alternative pathway in disease progression and in evaluating potential therapeutic strategies. Additionally, it serves as a tool in preclinical studies to assess the efficacy of targeting the complement system for treating inflammatory conditions.